ADC Therapeutics SA (ADCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ADC Therapeutics SA (ADCT) has a cash flow conversion efficiency ratio of 0.124x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.63 Million) by net assets ($-238.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ADC Therapeutics SA - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how ADC Therapeutics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of ADC Therapeutics SA for a breakdown of total debt and financial obligations.
ADC Therapeutics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ADC Therapeutics SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hunan Creator Information Technologies Co Ltd Class A
SHE:300730
|
-0.004x |
|
Xinjiang Sayram Modern Agriculture Co Ltd
SHG:600540
|
-1.614x |
|
Hearts and Minds Investments Ltd
AU:HM1
|
-0.004x |
|
AnHui Annada Titanium Industry Co Ltd
SHE:002136
|
-0.008x |
|
Spin Master Corp
TO:TOY
|
0.044x |
|
Xinjiang Baihuacun Co Ltd
SHG:600721
|
0.022x |
|
Wilson Bayly Holmes Ovcon Ltd
JSE:WBO
|
0.150x |
|
Teladan Prima Agro PT Tbk
JK:TLDN
|
0.132x |
Annual Cash Flow Conversion Efficiency for ADC Therapeutics SA (2017–2024)
The table below shows the annual cash flow conversion efficiency of ADC Therapeutics SA from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market value of ADC Therapeutics SA.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-202.64 Million | $-123.83 Million | 0.611x | -23.67% |
| 2023-12-31 | $-148.25 Million | $-118.69 Million | 0.801x | +145.99% |
| 2022-12-31 | $79.45 Million | $-138.31 Million | -1.741x | -23.89% |
| 2021-12-31 | $166.09 Million | $-233.38 Million | -1.405x | -179.40% |
| 2020-12-31 | $335.50 Million | $-168.73 Million | -0.503x | +54.02% |
| 2019-12-31 | $111.16 Million | $-121.58 Million | -1.094x | -13.78% |
| 2018-12-31 | $126.24 Million | $-121.36 Million | -0.961x | -219.61% |
| 2017-12-31 | $249.17 Million | $-74.94 Million | -0.301x | -- |
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the Chi… Read more